Assessment of polymeric mucin-drug interactions

PLoS One. 2024 Jun 27;19(6):e0306058. doi: 10.1371/journal.pone.0306058. eCollection 2024.

Abstract

Mucosal-delivered drugs have to pass through the mucus layer before absorption through the epithelial cell membrane. Although there has been increasing interest in polymeric mucins, a major structural component of mucus, potentially acting as important physiological regulators of mucosal drug absorption, there are no reports that have systematically evaluated the interaction between mucins and drugs. In this study, we assessed the potential interaction between human polymeric mucins (MUC2, MUC5B, and MUC5AC) and various drugs with different chemical profiles by simple centrifugal method and fluorescence analysis. We found that paclitaxel, rifampicin, and theophylline likely induce the aggregation of MUC5B and/or MUC2. In addition, we showed that the binding affinity of drugs for polymeric mucins varied, not only between individual drugs but also among mucin subtypes. Furthermore, we demonstrated that deletion of MUC5AC and MUC5B in A549 cells increased the cytotoxic effects of cyclosporin A and paclitaxel, likely due to loss of mucin-drug interaction. In conclusion, our results indicate the necessity to determine the binding of drugs to mucins and their potential impact on the mucin network property.

MeSH terms

  • A549 Cells
  • Cyclosporine / pharmacology
  • Drug Interactions
  • Humans
  • Mucin 5AC* / genetics
  • Mucin 5AC* / metabolism
  • Mucin-2 / genetics
  • Mucin-2 / metabolism
  • Mucin-5B / genetics
  • Mucin-5B / metabolism
  • Mucins / metabolism
  • Paclitaxel* / metabolism
  • Paclitaxel* / pharmacology
  • Protein Binding
  • Rifampin / pharmacology

Substances

  • Paclitaxel
  • Mucin 5AC
  • Mucin-5B
  • MUC5AC protein, human
  • Mucins
  • Mucin-2
  • Rifampin
  • Cyclosporine
  • MUC5B protein, human
  • MUC2 protein, human

Grants and funding

This work was supported by a research grant from The Mochida Memorial Foundation for Medical and Pharmaceutical Research (H.K.), JSPS KAKENHI (grant number 21K06695, H.K.) and The Helen Muir Fund (Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, D.J.T.). The Wellcome Centre for Cell-Matrix Research is supported by core funding from Wellcome [grant number 203128/A/16/Z, D.J.T.].